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Arthropathy is one of the most frequent clinical com-
plications of acromegaly. At presentation, some 60–70%
of patients have involvement of large peripheral joints
(shoulder, knee, hip) and about 50% have axial arthropa-
thy affecting mainly the lumbar area [1–3]. Elevated
circulating and likely autocrine IGF-1 is the driving
mechanism leading to joint involvement in this dis-
ease [4]. Degenerative osteoarthropathy was detected
in 43% of cats with GH-producing pituitary tumors [5].
Conversely, GH deficiency is a powerful protective
mechanism against aging-associated degenerative joint
disease [6].
Arthropathy may present as the earliest clinical
symptom of acromegaly in a significant proportion of
patients [7], and its prevalence and severity worsen with
the duration of uncontrolled disease [3].
The pathogenesis of arthropathy in acromegaly is
comprised of two mechanisms: initial endocrine and
subsequent mechanical changes. The understanding of
the bi-phasic nature of arthropathy is important for de-
signing appropriate therapeutic strategies.
Early in the course of the disease, elevated GH and
IGF-1 levels promote growth of the articular cartilage
and periarticular ligaments. As a result, the cartilage lin-
ing thickens and the joint space becomes “congested”
with ensuing limitation in the range of movements. At
the same time, overgrown ligaments cause laxity of the
joint. This stage is likely to occur very early in the
course of acromegaly and is fully reversible, as evi-
denced by the clinical course of arthropathy in patients
with hypopituitarism overtreated with GH [8]. If allowed
to persist, the altered joint geometry results in repeat
intra-articular trauma and exuberant reparative reac-
tions which leads to scar, cyst and osteophyte formation
with further worsening of joint geometry. The vicious
circle of “trauma-growth-trauma” is thus turned on, and
the disease acquires the characteristics and the features
of degenerative joint disease. Johanson et al. [9] pro-
vided a unique description of 11 surgical specimens from
acromegalic patients who had total hip arthroplasty and
compared them to the findings in patients with DJD.
The extent of osteophytes, synovitis and pitting of the
subchondral bone in acromegalic patients were qualita-
tively similar but more pronounced in acromegaly.
Obviously, when the disease is allowed to progress
that far, the changes become irreversible and biochem-
ical control of acromegaly, as evidenced by a normal
IGF-1, will have limited, if any, efficacy in improving the
clinical status of the patient.
Early studies on the reversibility of joint involvement
in acromegaly were uniformly pessimistic. Dons et al.
[7] studied 90 patients treated primarily by external pi-
tuitary radiotherapy. Five or more years after XRT, only
13% of patients were unaffected by arthropathy, and it
actually became worse in 2/3 of the group. These results
are not surprising as XRT has a very slow effect on GH
hypersecretion and limited efficacy in terms of normaliz-
ing plasma IGF-1. Surgical series were no more effective.
Whereas Lacks et al. [10] provided anecdotal evidence
of resolution of arthropathy in 2 patients after pituitary
surgery, Roelfsema et al. [11] had less encouraging re-
sults. In a series of 60 patients treated by surgery, plasma
GH fell to “normal” in 62%. Despite that seemingly salu-
tary result, resolution of arthropathy was “seldom seen”
even after a mean follow-up of 3.3 years. Part of this
discouraging outcome might have been due to the al-
ready irreversible nature of the joint disease, but persis-
tently high IGF-1 levels were likely maintained, even in
some patients with plasma GH below 2.5 microgram µ/L,
perpetuating the progression of arthropathy.
Layton et al. [3] were the first to examine the clini-
cal response of acromegalic arthropathy to the potent
GH-lowering agent, octreotide. A mild-to-moderate im-
provement in symptoms, estimated functional ability
and in crepitus occurred in 8 of 9 patients. Colao et al.
[12,13] pioneered the technique of ultrasound assess-
ment of articular cartilage thickness in acromegaly. They
have shown that articular cartilage almost doubles in
thickness in all major joints (shoulder, knee, wrist) in
active acromegaly and shrinks (but does not normalize)
in patients with inactive disease [12]. Treatment with oc-
treotide decreased cartilage thickness primarily in non-
weight bearing joints and effected clinical improvement.
In a subsequent study, the same group examined the
effects of lanreotide therapy. Again, a decrease in
cartilage thickness and marked clinical improvement
were observed in virtually all patients in parallel with
normalization of plasma IGF-1 [13]. Interestingly, the
effect sometimes required as long as 12 months of
therapy.
Thus, aggressive therapy of acromegaly aimed at
normalization of plasma IGF-1 is a prerequisite for
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successful control of arthropathy. This often requires
multiple therapeutic modalities including surgery, phar-
macotherapy and, in some cases, pituitary irradiation.
Obviously, not all patients will obtain sufficient symp-
tomatic relief from normalization of their GH/IGF-1
milieu. Any residual morbidity has to be dealt with us-
ing traditional methods: physical therapy, NSAIDs, local
steroid injections or, in advanced cases, surgical inter-
ventions (including joint replacement).
To obtain the best chance of sparing the patient
the agony and the disability of acromegalic arthropa-
thy, the disease should be optimally diagnosed as early
as possible and treated aggressively from the outset.
Normalization of plasma IGF-1 is currently the best
available monitoring tool, although means of assess-
ment of the magnitude of autocrine IGF-1 production
would be highly desirable.
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